Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies

Ding, Xian Fei; Liang, Huo Yan; Yuan, Bo; Li, Li Feng; Kan, Quan Cheng; Wang, Le Xin

doi:10.1186/s13287-019-1162-8

Cited by 15 publications

(7 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While immunogenicity is unrelated to MSC therapy [43,44], other significant risks still exist. Previous meta-analyses have shown no direct relationship between MSC administration and acute poisoning, systemic failure, malignancy, or death [47][48][49]. Regarding the safety and effectiveness of MSCs in the treatment of sepsis, phase 1 clinical trials have been conducted [43,44], but MSCs have not yet been used for the clinical treatment of sepsis.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Multiple studies have reported that mesenchymal stem cell (MSC) therapy has beneficial effects in experimental models of sepsis. However, this finding remains inconclusive. This study was performed to systematically determine the connection between MSC therapy and mortality in sepsis animal models by pooling and analyzing data from newly published studies. Methods: A detailed search of related studies from 2009 to 2019 was conducted in four databases, including MEDLINE, EMBASE, Cochrane Library, and Web of Science. After browsing and filtering out articles that met the inclusion criteria for statistical analysis, the inverse variance method of the fixed effects model was used to calculate the pooled odds ratios (ORs) and their 95% confidence intervals (CIs). Results: Twenty-nine animal studies, including 1266 animals, were identified. None of the studies was judged to have a low risk of bias. The meta-analysis demonstrated that MSC therapy was related to a significantly lower mortality rate (OR 0.29, 95% CI 0.22-0.38, P < 0.001). Subgroup analyses performed based on the MSC injection dose (< 1.0 × 10 6 cells, OR = 0.33, 95% CI 0.20-0.56, P < 0.001; 1.0 × 10 6 cells, OR = 0.24, 95% CI 0.16-0.35, P < 0.001) and injection time (< 1 h, OR = 0.24, 95% CI 0.13-0.45, P < 0.001; 1 h, OR = 0.28, 95% CI 0.17-0.46, P < 0.001) demonstrated that treatment with MSCs significantly reduced the mortality rate of animals with sepsis. Conclusion: This up-to-date meta-analysis showed a connection between MSC therapy and lower mortality in sepsis animal models, supporting the potential therapeutic effect of MSC treatment in future clinical trials. The results in this study contradict a previous meta-analysis with regards to the ideal dose of MSC therapy. Thus, further research is required to support these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis of results suggested that SC therapy significantly improves mPAP and RVSP in PAH animals, indicating that SC treatment for PAH has promising prospects, particularly induced pluripotent stem cells. Unfortunately, the detailed dose–effect of SCs and their efficacy for PAH requires further study to provide standardization for clinical trials [ 139 ]. Moreover, increasing research has implied that imbalance in the immune response also participates in the pathogenesis of PAH.…”

Section: Therapy For Pahmentioning

confidence: 99%

Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension

Zhang

Xiao

et al. 2022

Chin Med

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a progressive and rare disease without obvious clinical symptoms that shares characteristics with pulmonary vascular remodeling. Right heart failure in the terminal phase of PAH seriously threatens the lives of patients. This review attempts to comprehensively outline the current state of knowledge on PAH its pathology, pathogenesis, natural medicines therapy, mechanisms and clinical studies to provide potential treatment strategies. Although PAH and pulmonary hypertension have similar pathological features, PAH exhibits significantly elevated pulmonary vascular resistance caused by vascular stenosis and occlusion. Currently, the pathogenesis of PAH is thought to involve multiple factors, primarily including genetic/epigenetic factors, vascular cellular dysregulation, metabolic dysfunction, even inflammation and immunization. Yet many issues regarding PAH need to be clarified, such as the “oestrogen paradox”. About 25 kinds monomers derived from natural medicine have been verified to protect against to PAH via modulating BMPR2/Smad, HIF-1α, PI3K/Akt/mTOR and eNOS/NO/cGMP signalling pathways. Yet limited and single PAH animal models may not corroborate the efficacy of natural medicines, and those natural compounds how to regulate crucial genes, proteins and even microRNA and lncRNA still need to put great attention. Additionally, pharmacokinetic studies and safety evaluation of natural medicines for the treatment of PAH should be undertaken in future studies. Meanwhile, methods for validating the efficacy of natural drugs in multiple PAH animal models and precise clinical design are also urgently needed to promote advances in PAH. Graphical Abstract

show abstract

“…A systematic review of preclinical animal studies including 29 articles reported effectivity of stem cell therapy for pulmonary arterial hypertension. 12 One clinical report including 2 adult cases of PH receiving stem cell therapy also showed clinical improvement. Reduction of oxygen therapy and increased activity index in one patient were noted after stem cell therapy, while another patient had improved clinical or PH condition.…”

Section: Discussionmentioning

confidence: 98%

Mesenchymal stem cells therapy in children with end-stage kidney disease

Hidayati¹,

Fahlevi²,

Puspitasari³

et al. 2022

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a major health problem worldwide, with increasing incidence and prevalence. While the incidence of CKD in children is relatively low, CKD contributes to major health problems and has many long-term effects.1 Chronic kidney disease is characterized by a gradual decline in kidney function over time. The Kidney Disease Improving Global Outcomes (KDIGO) report defined CKD as an abnormality of renal structure or function with decreased glomerular filtration rate (GFR) that lasts more than three months. Chronic kidney disease is classified into 5 stages based on the GFR value.2 Patients with stage V CKD transition from progressive disease to irreversible, terminal, end-stage kidney disease (ESKD). To date, the standard of ESKD management has been kidney replacement therapy, consisting of hemodialysis (HD), peritoneal dialysis (PD), and/or kidney transplantation. Complexity and cost of kidney care have obvious consequences on the availability of kidney replacement therapy for children, especially in developing countries. Dialysis provides only partial replacement of renal functions, especially clearance and fluid balance, but does not cure the disease. Kidney transplantation is a curative management, but donor availability for pediatric patients remains challenging

show abstract

Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies

Cited by 15 publications

References 61 publications

Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies

Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies

Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension

Mesenchymal stem cells therapy in children with end-stage kidney disease

Contact Info

Product

Resources

About